Eli Lilly and Company announced an investment of over $6 billion to build a pharmaceutical manufacturing facility in Huntsville, Alabama. This will be the largest private industrial investment in Alabama’s history. The facility will be located on a 260-acre site at the intersection of I-565 and Greenbrier Parkway in Huntsville-Limestone County. It will focus on producing small molecule synthetic and peptide medicines, including oral GLP-1 products used to treat diabetes and obesity.
The project is expected to create 450 jobs, including roles for engineers, scientists, operations staff, and lab technicians. Construction is planned to start in 2026 and finish by 2032. This will be the third of four new U.S. manufacturing sites Lilly plans to announce. The company’s total U.S. capital expansion commitments have reached over $50 billion since 2020.
Lilly cited Huntsville’s workforce, infrastructure, and experience in advanced manufacturing as reasons for choosing the location. Company representatives noted the city’s background in technology and manufacturing. The investment aims to strengthen the domestic supply chain for pharmaceuticals and improve access to medicines in the U.S. and abroad…